Menu
Search
|

Menu

Close
X

ContraVir Pharmaceuticals Inc CTRV.OQ (NASDAQ Stock Exchange Capital Market)

1.04 USD
-- (--)
As of 1:30 AM IST
chart
Previous Close 1.04
Open --
Volume --
3m Avg Volume 22,849
Today’s High --
Today’s Low --
52 Week High 6.56
52 Week Low 1.00
Shares Outstanding (mil) 78.00
Market Capitalization (mil) 48.36
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.341
FY17
-1.418
FY16
-5.097
FY15
-7.747
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
5.85
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.72
LT Debt to Equity (MRQ)
vs sector
0.00
12.39
Return on Investment (TTM)
vs sector
-126.93
14.61
Return on Equity (TTM)
vs sector
--
16.34

EXECUTIVE LEADERSHIP

Gary Jacob
Chairman of the Board of Directors, Since 2014
Salary: --
Bonus: --
James Sapirstein
Chief Executive Officer, Director, Since 2014
Salary: $410,000.00
Bonus: --
John Cavan
Chief Financial Officer, Since 2016
Salary: --
Bonus: --
Theresa Matkovits
Chief Operating Officer, Since 2016
Salary: $275,000.00
Bonus: --
Robert Foster
Chief Scientific Officer, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

399 Thornall St
EDISON   NJ   08837-2236

Phone: +1732.9024000

ContraVir Pharmaceuticals, Inc. is focused on curing hepatitis B through the combination of direct and indirect acting antiviral compounds. Its two assets tenofovir exalidex, or TXL, and CRV431 have complementary mechanisms of action and have shown potential synergy against hepatitis B virus (HBV). TXL is designed to deliver high intrahepatic concentrations of TFV while minimizing off target effects caused by high levels of circulating TFV, and has completed a Phase IIa trial. CRV431, the other anti-HBV compound, is a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. In vitro and in vivo studies have thus far demonstrated that CRV431 reduces HBV DNA and other viral proteins, including surface antigen (HBsAg).

SPONSORED STORIES